Abstracts of the 12 th Congress of ECCO – European Crohn’s and Colitis Organisation S447 P716 Beta-blocker use is associated with a higher relapse risk of inflammatory bowel disease – a Dutch retrospective cohort study R. Willemze* 1 , T. Bakker 1 , M. Pippias 2 , C. Ponsioen 3 , W. de Jonge 1 1 Academic Medical Center (AMC), Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands; 2 Academic Medical Center (AMC), Department of Medical Informatics, Amsterdam, Netherlands; 3 Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands Background: Inflammatory bowel disease (IBD) is a multifactorial disease and as such, many factors may influence the disease course – like the concomitant use of medication. One such drug group is beta-blockers, a medication group primarily prescribed for the treat- ment of cardiovascular disease, which is used by approximately 10% of the Dutch population. Beta-blockers block the β-adrenergic recep- tors. β-adrenergic receptor activation has potent anti-inflammatory effects on the myeloid compartment of the immune system. In this pilot study, we addressed whether an association exists be- tween the use of beta-blockers and the course of IBD, as defined by the risk of a disease relapse in patients with IBD. Methods: In this retrospective cohort study design, we used a population-based IBD cohort of 1461 patients. We identified relapses using medication prescriptions as a proxy. We calculated the number of relapses per 100 person-years and compared this between IBD pa- tients using beta-blockers and IBD patients not using beta-blockers. We used Cox proportional hazards models with shared frailty to compare the risk of a relapse between both groups. Results: 250 IBD patients had available prescriptions and were in- cluded in the study, 30 patients (12%) used a beta-blocker. In the beta-blocker group, there were 21 relapses per 100 person-years (95% confidence interval (CI): 14.0–28.6) versus 29 relapses per 100 person-years (95% CI: 26.2–32.4) in the group of patients that did not use a beta-blocker. However, when we used the Cox proportional hazard model with shared frailty and adjusted for age and gender we observed a 54% higher risk of a relapse in the group of IBD pa- tients that used a beta-blocker versus the IBD patients that did not use a beta-blocker (adjusted hazard ratio: 1.54, 95% CI: 1.05–2.25; p=0.03). Conclusions: The results of our study suggest that beta-blocker use is associated with an increased risk of disease relapses in patients with IBD. Indeed, concomitant medication use seems to be one of the factors that can influence the course of IBD and this should be acknowledged while making decisions about treatment of IBD and follow-up. These results warrant confirmation in a larger cohort. P717 Higher ulcerative colitis/Crohn’s disease ratio in a central region of Argentina D. Balderramo* 1 , P. Herrera-Najum 2 , J. Trakal 3 , R. Gonzalez 1 , F. Zárate 4 , K. Raiden 5 , L. Ferrer 2 , S. Balzola 5 , M.R. Defagó 6 , Grupo CEMEI (Cooperación para el Estydio y Manejo de la Enfermedad Inflamatoria Intestinal) Córdoba, Argentina 1 Hospital Privado Universitario de Cordoba, Gastroenterology De- partment, Cordoba, Argentina; 2 Instituto Modelo de Cardiolo- gia, Gastroenterology Department, Cordoba, Argentina; 3 Clínica Reina Fabiola, Gastroenterology Department, Cordoba, Ar- gentina; 4 Hospital Córdoba, Gastroenterology Department, Cor- doba, Argentina; 5 Sanatorio Allende, Gastroenterology Department, Cordoba, Argentina; 6 Humana-Instituto Médico Privado/Conci- Carpinella, Gastroenterology Department, Cordoba, Argentina Background: The prevalence of inflammatory bowel disease (IBD) has increased worldwide. However, there are few studies that de- scribed the epidemiology and clinical behavior of IBD in South Amer- ica. The aim of this study was to describe phenotype and clinical evolution of IDB in a central city from Argentina. Methods: We performed a descriptive observational study in order to describe all patients with IBD diagnosis that assisted to ten cen- ters (public and private) from Córdoba city (Argentina) between 06/2014–09/2016. Córdoba is the second largest city in popula- tion from Argentina with 1,300,000 inhabitants and represents al- most 3.3% of the country population. During the registry data were recorded on standardized forms and information on demography, clinical evolution, endoscopic finding, and therapy were evaluated. Results: A total of 454 patients were included. The ratio of ulcera- tive colitis (UC) (n=394, 86.8%) and Crohn’s disease (CD) (n=56, 12.3%) was 7.04: 1. Mean age at diagnosis was 39.5 years (SD 16.4), with similar distribution by gender. At the moment of diag- nosis, diarrhea and bleeding were more frequent manifestations in patients with UC; and abdominal pain and weight loss were the main presentation in patients with CD. Extra intestinal manifesta- tions (with a predominance of joint involvement) were present in 20.2% of patients and were similar in UC and CD. The distribution of UC was: 34.18% proctitis, 48.72% left colitis and 17.1% pan- colitis. The most common site of involvement in CD patients was: 45% colonic, 25.7% ileocolonic, 17% ileum, and 2.3% had upper gastrointestinal tract involvement. The phenotype of CD was 42.1% inflammatory, 31.6% fibrostenotic, 10.5% perianal, and 15.8% fis- tulizing/perforating. Anti-TNF therapy was used in 2.3% of patients with UC compared to 26.7% of patients with CD (p<0.001). The rate of surgery was 3.8% for patients with UC compared to 41% in patients with CD (p<0.001). CD patients with inflammatory and fibrostenotic behavior presented a lower percentage of surgery. Conclusions: We observed a predominance of UC in our popula- tion with lower rate of anti-TNF therapy and surgery. Compared to other series in South America, patients with CD diagnosis presented a higher frequency colonic involvement and lower need of anti-TNF therapy. P718 The epidemiology of IBD differs in South Asian migrants compared to Caucasians; results from a systematic review and meta-analysis R. Misra* 1 , O. Faiz 2 , J. Burisch 3 , P. Munkholm 3 , N. Arebi 4 1 St. Mark’s Academic Institute, Gastroenterology, London, United Kingdom; 2 St Mark’s Academic Institute, Surgical Epidemiology, Tri- als and Outcomes Unit (SETOC), London, United Kingdom; 3 North Zealand University Hospital, Gastroenterology, Frederikssund, Den- mark; 4 St Mark’s Academic Institute, Gastroenterology, London, United Kingdom Background: Migrants from eastern low incidence countries are re- ported to develop the incidence of their adopted country. The South Asian (SA) community has a wide diaspora and presents an ideal group to study migration. We aimed to summarise the epidemiology of IBD in SA migrants through a systematic literature review and meta-analysis. Methods: Studies reporting the incidence of IBD in SA migrants com- pared with Caucasian groups were eligible for inclusion. Quality as- Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/11/suppl_1/S447/2961660 by guest on 20 May 2020